BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7:e34156. [PMID: 22479548 DOI: 10.1371/journal.pone.0034156] [Cited by in Crossref: 123] [Cited by in F6Publishing: 125] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J, Avihingsanon A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger EC, Egger M; International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis 2019;19:298-307. [PMID: 30744962 DOI: 10.1016/S1473-3099(18)30673-X] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 12.5] [Reference Citation Analysis]
2 Karanja M, Kingwara L, Owiti P, Kirui E, Ngari F, Kiplimo R, Maina M, Masini E, Onyango E, Ngugi C. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data. PLoS One 2020;15:e0234588. [PMID: 33264300 DOI: 10.1371/journal.pone.0234588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bock P, Cox H. Acute care - an important component of the continuum of care for HIV and tuberculosis in developing countries. Anaesthesia 2017;72:147-50. [PMID: 27869303 DOI: 10.1111/anae.13604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Date A, Modi S. TB screening among people living with HIV/AIDS in resource-limited settings. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S270-3. [PMID: 25768866 DOI: 10.1097/QAI.0000000000000485] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
5 Akanbi MO, Achenbach CJ, Feinglass J, Taiwo B, Onu A, Pho MT, Agbaji O, Kanki P, Murphy RL. Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study. AIDS Res Hum Retroviruses 2013;29:931-7. [PMID: 23316724 DOI: 10.1089/AID.2012.0231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 van Woudenbergh E, Irvine EB, Davies L, de Kock M, Hanekom WA, Day CL, Fortune S, Alter G. HIV Is Associated with Modified Humoral Immune Responses in the Setting of HIV/TB Coinfection. mSphere 2020;5:e00104-20. [PMID: 32434838 DOI: 10.1128/mSphere.00104-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kufa T, Mabuto T, Muchiri E, Charalambous S, Rosillon D, Churchyard G, Harris RC. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One 2014;9:e111209. [PMID: 25393281 DOI: 10.1371/journal.pone.0111209] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
8 Dravid A, Natarajan K, Medisetty M, Gawali R, Mahajan U, Kulkarni M, Saraf C, Ghanekar C, Kore S, Rathod N, Dravid M. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India. BMC Infect Dis 2019;19:714. [PMID: 31409289 DOI: 10.1186/s12879-019-4361-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Lawn SD. Enhancing the impact of antiretroviral scale-up on the HIV-associated tuberculosis epidemic in Malawi. Public Health Action 2014;4:204. [PMID: 26393084 DOI: 10.5588/pha.14.0067] [Reference Citation Analysis]
10 Pearl JE, Das M, Cooper AM. Immunological roulette: Luck or something more? Considering the connections between host and environment in TB. Cell Mol Immunol 2018;15:226-32. [PMID: 29375129 DOI: 10.1038/cmi.2017.145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Namdev P, Patel S, Sparling B, Garg A. Monocytic-Myeloid Derived Suppressor Cells of HIV-Infected Individuals With Viral Suppression Exhibit Suppressed Innate Immunity to Mycobacterium tuberculosis. Front Immunol 2021;12:647019. [PMID: 33995365 DOI: 10.3389/fimmu.2021.647019] [Reference Citation Analysis]
12 Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW. Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. J Infect Dis 2021;223:1621-30. [PMID: 32915986 DOI: 10.1093/infdis/jiaa580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Mollel EW, Chilongola JO. Predictors for Mortality among Multidrug-Resistant Tuberculosis Patients in Tanzania. J Trop Med 2017;2017:9241238. [PMID: 28808447 DOI: 10.1155/2017/9241238] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
14 Gupta RK, Rice B, Brown AE, Thomas HL, Zenner D, Anderson L, Pedrazzoli D, Pozniak A, Abubakar I, Delpech V, Lipman M. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV 2015;2:e243-51. [PMID: 26423197 DOI: 10.1016/S2352-3018(15)00063-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
15 Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya. PLoS One 2017;12:e0188235. [PMID: 29145454 DOI: 10.1371/journal.pone.0188235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
16 Tweya H, Feldacker C, Mpunga J, Kanyerere H, Heller T, Ganesh P, Nkosi D, Kalulu M, Sinkala G, Satumba T, Phiri S. The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi. J Int AIDS Soc 2019;22:e25240. [PMID: 31038836 DOI: 10.1002/jia2.25240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, Motsamai OI, Shang N, Rose CE, Shepherd J. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS 2015;29:351-9. [PMID: 25686683 DOI: 10.1097/QAD.0000000000000535] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
18 Hoffman RM, Angelidou KN, Brummel SS, Saidi F, Violari A, Dula D, Mave V, Fairlie L, Theron G, Kamateeka M, Chipato T, Chi BH, Stranix-Chibanda L, Nematadzira T, Moodley D, Bhattacharya D, Gupta A, Coletti A, McIntyre JA, Klingman KL, Chakhtoura N, Shapiro DE, Fowler MG, Currier JS; IMPAACT PROMISE 1077BF/FF team. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clin Trials 2018;19:209-24. [PMID: 30890061 DOI: 10.1080/15284336.2018.1537327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc 2012;15:17396. [PMID: 22905358 DOI: 10.7448/ias.15.2.17396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
20 Takarinda KC, Harries AD, Sandy C, Mutasa-Apollo T, Zishiri C. Declining tuberculosis case notification rates with the scale-up of antiretroviral therapy in Zimbabwe. Public Health Action 2016;6:164-8. [PMID: 27695678 DOI: 10.5588/pha.16.0029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 Pathmanathan I, Pevzner E, Cavanaugh J, Nelson L. Addressing tuberculosis in differentiated care provision for people living with HIV. Bull World Health Organ 2017;95:3. [PMID: 28053356 DOI: 10.2471/BLT.16.187021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 Wolday D, Kebede Y, Legesse D, Siraj DS, McBride JA, Kirsch MJ, Striker R. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. PLoS One 2020;15:e0233049. [PMID: 32442166 DOI: 10.1371/journal.pone.0233049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Dhungana GP, Thekkur P, Chinnakali P, Bhatta U, Pandey B, Zhang WH. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ Open 2019;9:e029058. [PMID: 31147370 DOI: 10.1136/bmjopen-2019-029058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Du Bruyn E, Wilkinson RJ. The Immune Interaction between HIV-1 Infection and Mycobacterium tuberculosis. Microbiol Spectr 2016;4. [PMID: 28084192 DOI: 10.1128/microbiolspec.TBTB2-0012-2016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 Harries AD, Lawn SD, Suthar AB, Granich R. Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation. Lancet Infect Dis 2015;15:1492-6. [PMID: 26515525 DOI: 10.1016/S1473-3099(15)00242-X] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
26 van Halsema CL, Okhai H, Hill T, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study. Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. AIDS 2020;34:1813-21. [PMID: 32501837 DOI: 10.1097/QAD.0000000000002599] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Walker NF, Meintjes G, Wilkinson RJ. HIV-1 and the immune response to TB. Future Virol 2013;8:57-80. [PMID: 23653664 DOI: 10.2217/fvl.12.123] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
28 Gerin M, Bourgarit A. [Interferon gamma release assay tests and HIV infection]. Rev Mal Respir 2018;35:883-6. [PMID: 30224209 DOI: 10.1016/j.rmr.2018.08.013] [Reference Citation Analysis]
29 Kumarasamy N, Poongulali S, Bollaerts A, Moris P, Beulah FE, Ayuk LN, Demoitié MA, Jongert E, Ofori-Anyinam O. A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults. Medicine (Baltimore) 2016;95:e2459. [PMID: 26817879 DOI: 10.1097/MD.0000000000002459] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
30 Liu E, Makubi A, Drain P, Spiegelman D, Sando D, Li N, Chalamilla G, Sudfeld CR, Hertzmark E, Fawzi WW. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS 2015;29:1391-9. [PMID: 26091295 DOI: 10.1097/QAD.0000000000000705] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 8.4] [Reference Citation Analysis]
31 Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, Chinnakali P, Nirgude AS, Rangaraju C, Somashekar N, Kumar AMV. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action 2020;13:1704540. [PMID: 31937200 DOI: 10.1080/16549716.2019.1704540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, van der Heijden Y, Wood R, Rustomjee R, Kana BD. Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infect Dis 2019;19:e65-76. [PMID: 30554995 DOI: 10.1016/S1473-3099(18)30477-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
33 Ryndak MB, Singh KK, Peng Z, Zolla-Pazner S, Li H, Meng L, Laal S. Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects. PLoS One 2014;9:e94939. [PMID: 24755630 DOI: 10.1371/journal.pone.0094939] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
34 Mupfumi L, Mpande CAM, Reid T, Moyo S, Shin SS, Zetola N, Mogashoa T, Musonda RM, Kasvosve I, Scriba TJ, Nemes E, Gaseitsiwe S. Immune Phenotype and Functionality of Mtb-Specific T-Cells in HIV/TB Co-Infected Patients on Antiretroviral Treatment. Pathogens 2020;9:E180. [PMID: 32131556 DOI: 10.3390/pathogens9030180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Rockwood N, Wilkinson RJ. Understanding and intervening in HIV-associated tuberculosis. Clin Med (Lond) 2015;15 Suppl 6:s43-9. [PMID: 26634681 DOI: 10.7861/clinmedicine.15-6-s43] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Lange C, van Leth F, Sester M; TBnet. Viral Load and Risk of Tuberculosis in HIV Infection. J Acquir Immune Defic Syndr 2016;71:e51-3. [PMID: 26761521 DOI: 10.1097/QAI.0000000000000834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
37 Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690. [PMID: 24835842 DOI: 10.1016/s0140-6736(14)60162-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 98] [Article Influence: 21.4] [Reference Citation Analysis]
38 Bjerrum S, Bonsu F, Hanson-Nortey NN, Kenu E, Johansen IS, Andersen AB, Bjerrum L, Jarbøl D, Munck A. Tuberculosis screening in patients with HIV: use of audit and feedback to improve quality of care in Ghana. Glob Health Action 2016;9:32390. [PMID: 27569593 DOI: 10.3402/gha.v9.32390] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Paquin-Proulx D, Costa PR, Terrassani Silveira CG, Marmorato MP, Cerqueira NB, Sutton MS, O'Connor SL, Carvalho KI, Nixon DF, Kallas EG. Latent Mycobacterium tuberculosis Infection Is Associated With a Higher Frequency of Mucosal-Associated Invariant T and Invariant Natural Killer T Cells. Front Immunol 2018;9:1394. [PMID: 29971068 DOI: 10.3389/fimmu.2018.01394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
40 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S297-305. [PMID: 25768869 DOI: 10.1097/QAI.0000000000000497] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
41 Gupta-Wright A, Wood R, Bekker LG, Lawn SD. Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service. J Acquir Immune Defic Syndr 2013;64:261-70. [PMID: 23846570 DOI: 10.1097/QAI.0b013e3182a23e9a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
42 Lima VD, Granich R, Phillips P, Williams B, Montaner JS. Potential impact of the US President's Emergency Plan for AIDS relief on the tuberculosis/HIV coepidemic in selected Sub-Saharan African countries. J Infect Dis 2013;208:2075-84. [PMID: 23911712 DOI: 10.1093/infdis/jit406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
43 Dodd PJ, Prendergast AJ, Beecroft C, Kampmann B, Seddon JA. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax 2017;72:559-75. [PMID: 28115682 DOI: 10.1136/thoraxjnl-2016-209421] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
44 Karo B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, Fiebig L; German ClinSurv HIV Study Group. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014;14:148. [PMID: 24646042 DOI: 10.1186/1471-2334-14-148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
45 Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS One 2013;8:e63596. [PMID: 23717451 DOI: 10.1371/journal.pone.0063596] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
46 Kerkhoff AD, Kranzer K, Samandari T, Nakiyingi-Miiro J, Whalen CC, Harries AD, Lawn SD. Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy. PLoS One 2012;7:e49928. [PMID: 23209621 DOI: 10.1371/journal.pone.0049928] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
47 Yuen CM, Weyenga HO, Kim AA, Malika T, Muttai H, Katana A, Nganga L, Cain KP, De Cock KM. Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012. PLoS One 2014;9:e99880. [PMID: 24937804 DOI: 10.1371/journal.pone.0099880] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
48 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
49 García-Basteiro AL, López-Varela E, Respeito D, González R, Naniche D, Manhiça I, Macete E, Cobelens F, Alonso PL. High tuberculosis burden among people living with HIV in southern Mozambique. Eur Respir J 2015;45:547-9. [PMID: 25395030 DOI: 10.1183/09031936.00145714] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
50 Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker LG, Lawn SD. The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study. BMC Med 2015;13:70. [PMID: 25889688 DOI: 10.1186/s12916-015-0320-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
51 Blaser N, Zahnd C, Hermans S, Salazar-Vizcaya L, Estill J, Morrow C, Egger M, Keiser O, Wood R. Tuberculosis in Cape Town: An age-structured transmission model. Epidemics 2016;14:54-61. [PMID: 26972514 DOI: 10.1016/j.epidem.2015.10.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
52 Bruyn ED, Fukutani KF, Rockwood N, Schutz C, Meintjes G, Arriaga MB, Cubillos-Angulo JM, Tibúrcio R, Sher A, Riou C, Wilkinson KA, Andrade BB, Wilkinson RJ. Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. Lancet Microbe 2021;2:e375-85. [PMID: 34386782 DOI: 10.1016/s2666-5247(21)00037-9] [Reference Citation Analysis]
53 Dai Y, Cai Y, Wang X, Zhu J, Liu X, Liu H, Li L, Zhang Y, Liu S, Wen Z, Feng CG, Chen X, Tang X. Autoantibody-Mediated Erythrophagocytosis Increases Tuberculosis Susceptibility in HIV Patients. mBio 2020;11:e03246-19. [PMID: 32098821 DOI: 10.1128/mBio.03246-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Larson EC, Ellis-Connell A, Rodgers MA, Balgeman AJ, Moriarty RV, Ameel CL, Baranowski TM, Tomko JA, Causgrove CM, Maiello P, O'Connor SL, Scanga CA. Pre-existing Simian Immunodeficiency Virus Infection Increases Expression of T Cell Markers Associated with Activation during Early Mycobacterium tuberculosis Coinfection and Impairs TNF Responses in Granulomas. J Immunol 2021:ji2100073. [PMID: 34145063 DOI: 10.4049/jimmunol.2100073] [Reference Citation Analysis]
55 Ganatra SR, Bucşan AN, Alvarez X, Kumar S, Chatterjee A, Quezada M, Fish A, Singh DK, Singh B, Sharan R, Lee TH, Shanmugasundaram U, Velu V, Khader SA, Mehra S, Rengarajan J, Kaushal D. Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model. J Clin Invest 2020;130:5171-9. [PMID: 32544085 DOI: 10.1172/JCI136502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
56 Saito S, Mpofu P, Carter EJ, Diero L, Wools-Kaloustian KK, Yiannoutsos CT, Beverly MS, Tsiouris S, Somi GR, Ssali J, Nash D, Elul B. Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012. J Acquir Immune Defic Syndr 2016;71:e96-e106. [PMID: 26910387 DOI: 10.1097/QAI.0000000000000896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
57 du Bruyn E, Peton N, Esmail H, Howlett PJ, Coussens AK, Wilkinson RJ. Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection. Curr Opin HIV AIDS 2018;13:455-61. [PMID: 30286038 DOI: 10.1097/COH.0000000000000501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
58 Lee SS, Lin HH, Tsai HC, Su IJ, Yang CH, Sun HY, Hung CC, Sy CL, Wu KS, Chen JK, Chen YS, Fang CT. A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study. PLoS One 2015;10:e0135801. [PMID: 26280669 DOI: 10.1371/journal.pone.0135801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
59 Otiende V, Achia T, Mwambi H. Bayesian modeling of spatiotemporal patterns of TB-HIV co-infection risk in Kenya. BMC Infect Dis 2019;19:902. [PMID: 31660883 DOI: 10.1186/s12879-019-4540-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, Howard AA. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS 2014;28:1463-72. [PMID: 24681417 DOI: 10.1097/QAD.0000000000000278] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
61 Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A 2014;111:5325-30. [PMID: 24706842 DOI: 10.1073/pnas.1317660111] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
62 Kerschberger B, Schomaker M, Telnov A, Vambe D, Kisyeri N, Sikhondze W, Pasipamire L, Ngwenya SM, Rusch B, Ciglenecki I, Boulle A. Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis. Trop Med Int Health 2019;24:1114-27. [PMID: 31310029 DOI: 10.1111/tmi.13290] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Henry RT, Jiamsakul A, Law M, Losso M, Kamarulzaman A, Phanuphak P, Kumarasamy N, Foulkes S, Mohapi L, Nwizu C, Wood R, Kelleher A, Polizzotto M; SECOND-LINE Study Group. Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants. J Acquir Immune Defic Syndr 2021;87:720-9. [PMID: 33399309 DOI: 10.1097/QAI.0000000000002619] [Reference Citation Analysis]
64 Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013;13:852-8. [PMID: 23954450 DOI: 10.1016/S1473-3099(13)70187-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
65 Auld SC, Staitieh BS. HIV and the tuberculosis "set point": how HIV impairs alveolar macrophage responses to tuberculosis and sets the stage for progressive disease. Retrovirology 2020;17:32. [PMID: 32967690 DOI: 10.1186/s12977-020-00540-2] [Reference Citation Analysis]
66 Ketema DB, Alene M, Assemie MA, Yismaw L, Merid MW. Risk factors for mortality among drug-resistant tuberculosis patients registered for drug-resistant treatment in Amhara region, Ethiopia: a historical cohort study. Arch Public Health 2020;78:69. [PMID: 32760587 DOI: 10.1186/s13690-020-00448-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Gunda DW, Maganga SC, Nkandala I, Kilonzo SB, Mpondo BC, Shao ER, Kalluvya SE. Prevalence and Risk Factors of Active TB among Adult HIV Patients Receiving ART in Northwestern Tanzania: A Retrospective Cohort Study. Can J Infect Dis Med Microbiol 2018;2018:1346104. [PMID: 30073038 DOI: 10.1155/2018/1346104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
68 Kassa D, Gebremichael G, Alemayehu Y, Wolday D, Messele T, van Baarle D. Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia. AIDS Res Ther 2013;10:18. [PMID: 23842109 DOI: 10.1186/1742-6405-10-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
69 Lal KG, Phuang-Ngern Y, Suhkumvittaya S, Leeansyah E, Alrubayyi A, Dias J, Waickman A, Kim D, Kroon E, Pinyakorn S, Eller LA, Maciel M Jr, Rerknimitr R, Chomchey N, Phanuphak N, de Souza MSS, Nitayaphan S, Ake JA, Vasan S, Robb ML, Ananworanich J, Sandberg JK, Schuetz A, Eller MA, Paquin-Proulx D. Longitudinal Analysis of Peripheral and Colonic CD161+ CD4+ T Cell Dysfunction in Acute HIV-1 Infection and Effects of Early Treatment Initiation. Viruses 2020;12:E1426. [PMID: 33322496 DOI: 10.3390/v12121426] [Reference Citation Analysis]
70 Hermans S, Cornell M, Middelkoop K, Wood R. The differential impact of HIV and antiretroviral therapy on gender-specific tuberculosis rates. Trop Med Int Health 2019;24:454-62. [PMID: 30681241 DOI: 10.1111/tmi.13209] [Reference Citation Analysis]
71 LaCourse SM, Cranmer LM, Matemo D, Kinuthia J, Richardson BA, John-Stewart G, Horne DJ. Tuberculosis Case Finding in HIV-Infected Pregnant Women in Kenya Reveals Poor Performance of Symptom Screening and Rapid Diagnostic Tests. J Acquir Immune Defic Syndr 2016;71:219-27. [PMID: 26334736 DOI: 10.1097/QAI.0000000000000826] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
72 Pretorius C, Menzies NA, Chindelevitch L, Cohen T, Cori A, Eaton JW, Fraser C, Gopalappa C, Hallett TB, Salomon JA, Stover J, White RG, Dodd PJ. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models. AIDS 2014;28 Suppl 1:S25-34. [PMID: 24468944 DOI: 10.1097/QAD.0000000000000085] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
73 Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, Waldrop G, Kranzer K, Doherty M, Getahun H. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc 2016;19:20714. [PMID: 26765347 DOI: 10.7448/IAS.19.1.20714] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 11.6] [Reference Citation Analysis]
74 Hermans S, Boulle A, Caldwell J, Pienaar D, Wood R. Temporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis. J Int AIDS Soc 2015;18:20240. [PMID: 26411694 DOI: 10.7448/IAS.18.1.20240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
75 Takarinda KC, Choto RC, Mutasa-Apollo T, Chakanyuka-Musanhu C, Timire C, Harries AD. Scaling up isoniazid preventive therapy in Zimbabwe: has operational research influenced policy and practice? Public Health Action 2018;8:218-24. [PMID: 30775283 DOI: 10.5588/pha.18.0051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
76 Desalegn G, Tsegaye A, Gebreegziabiher D, Aseffa A, Howe R. Enhanced IFN-γ, but not IL-2, response to Mycobacterium tuberculosis antigens in HIV/latent TB co-infected patients on long-term HAART. BMC Immunol 2019;20:35. [PMID: 31601184 DOI: 10.1186/s12865-019-0317-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
77 Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One 2013;8:e55824. [PMID: 23418463 DOI: 10.1371/journal.pone.0055824] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
78 Harries AD, Kumar AMV, Satyanarayana S, Thekkur P, Lin Y, Dlodlo RA, Khogali M, Zachariah R. The Growing Importance of Tuberculosis Preventive Therapy and How Research and Innovation Can Enhance Its Implementation on the Ground. Trop Med Infect Dis 2020;5:E61. [PMID: 32316300 DOI: 10.3390/tropicalmed5020061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
79 Mupfumi L, Moyo S, Molebatsi K, Thami PK, Anderson M, Mogashoa T, Iketleng T, Makhema J, Marlink R, Kasvosve I, Essex M, Musonda RM, Gaseitsiwe S. Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana. PLoS One 2018;13:e0192030. [PMID: 29385208 DOI: 10.1371/journal.pone.0192030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
80 Siddiqui S, Sarro Y, Diarra B, Diallo H, Guindo O, Dabitao D, Tall M, Hammond A, Kassambara H, Goita D, Dembele P, Traore B, Hengel R, Nason M, Warfield J, Washington J, Polis M, Diallo S, Dao S, Koita O, Lane HC, Catalfamo M, Tounkara A. Tuberculosis specific responses following therapy for TB: Impact of HIV co-infection. Clin Immunol 2015;159:1-12. [PMID: 25889622 DOI: 10.1016/j.clim.2015.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
81 Moodley Y, Govender K. A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa. Afr Health Sci 2015;15:1239-46. [PMID: 26958026 DOI: 10.4314/ahs.v15i4.24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Agizew T, Surie D, Oeltmann JE, Letebele M, Pals S, Mathebula U, Mathoma A, Kassa M, Hamda S, Pono P, Rankgoane-Pono G, Boyd R, Auld A, Finlay A. Tuberculosis preventive treatment opportunities at antiretroviral therapy initiation and follow-up visits. Public Health Action 2020;10:64-9. [PMID: 32639479 DOI: 10.5588/pha.19.0056] [Reference Citation Analysis]
83 Zawedde-Muyanja S, Manabe YC, Musaazi J, Mugabe FR, Ross JM, Hermans S. Anti-retroviral therapy scale-up and its impact on sex-stratified tuberculosis notification trends in Uganda. J Int AIDS Soc 2019;22:e25394. [PMID: 31529618 DOI: 10.1002/jia2.25394] [Reference Citation Analysis]
84 Kanyerere H, Harries AD, Tayler-Smith K, Jahn A, Zachariah R, Chimbwandira FM, Mpunga J. The rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy. Trop Med Int Health 2016;21:101-7. [PMID: 26509352 DOI: 10.1111/tmi.12630] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
85 Dodd PJ, Knight GM, Lawn SD, Corbett EL, White RG. Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis. PLoS One 2013;8:e75466. [PMID: 24069418 DOI: 10.1371/journal.pone.0075466] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
86 Maartens G, Boffito M, Flexner CW. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. Curr Opin HIV AIDS 2017;12:355-8. [PMID: 28403028 DOI: 10.1097/COH.0000000000000376] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
87 Ellis AL, Balgeman AJ, Larson EC, Rodgers MA, Ameel C, Baranowski T, Kannal N, Maiello P, Juno JA, Scanga CA, O'Connor SL. MAIT cells are functionally impaired in a Mauritian cynomolgus macaque model of SIV and Mtb co-infection. PLoS Pathog 2020;16:e1008585. [PMID: 32433713 DOI: 10.1371/journal.ppat.1008585] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
88 Roff SR, Noon-Song EN, Yamamoto JK. The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol 2014;4:498. [PMID: 24454311 DOI: 10.3389/fimmu.2013.00498] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
89 Ayelign B, Workneh M, Molla MD, Dessie G. Role Of Vitamin-D Supplementation In TB/HIV Co-Infected Patients. Infect Drug Resist 2020;13:111-8. [PMID: 32021325 DOI: 10.2147/IDR.S228336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
90 Teklu AM, Nega A, Mamuye AT, Sitotaw Y, Kassa D, Mesfin G, Belayihun B, Medhin G, Yirdaw K. Factors Associated with Mortality of TB/HIV Co-infected Patients in Ethiopia. Ethiop J Health Sci 2017;27:29-38. [PMID: 28465651 DOI: 10.4314/ejhs.v27i1.4s] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
91 Lawn SD, Kerkhoff AD, Vogt M, Wood R. HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays. BMC Med 2013;11:231. [PMID: 24168211 DOI: 10.1186/1741-7015-11-231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
92 Xu W, Snell LM, Guo M, Boukhaled G, Macleod BL, Li M, Tullius MV, Guidos CJ, Tsao MS, Divangahi M, Horwitz MA, Liu J, Brooks DG. Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection. Immunity 2021;54:526-541.e7. [PMID: 33515487 DOI: 10.1016/j.immuni.2021.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
93 Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitié MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 2014;28:1769-81. [PMID: 24911353 DOI: 10.1097/QAD.0000000000000343] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
94 Bunyasi EW, Mulenga H, Luabeya AKK, Shenje J, Mendelsohn SC, Nemes E, Tameris M, Wood R, Scriba TJ, Hatherill M. Regional changes in tuberculosis disease burden among adolescents in South Africa (2005-2015). PLoS One 2020;15:e0235206. [PMID: 32609738 DOI: 10.1371/journal.pone.0235206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
95 Bell LC, Breen R, Miller RF, Noursadeghi M, Lipman M. Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. Int J Infect Dis 2015;32:39-45. [PMID: 25809754 DOI: 10.1016/j.ijid.2014.12.030] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
96 Meintjes G, Kerkhoff AD, Burton R, Schutz C, Boulle A, Van Wyk G, Blumenthal L, Nicol MP, Lawn SD. HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up. Medicine (Baltimore) 2015;94:e2269. [PMID: 26683950 DOI: 10.1097/MD.0000000000002269] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 7.6] [Reference Citation Analysis]
97 Bock P, Jennings K, Vermaak R, Cox H, Meintjes G, Fatti G, Kruger J, De Azevedo V, Maschilla L, Louis F, Gunst C, Grobbelaar N, Dunbar R, Limbada M, Floyd S, Grimwood A, Ayles H, Hayes R, Fidler S, Beyers N. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa. J Acquir Immune Defic Syndr 2018;77:93-101. [PMID: 29016524 DOI: 10.1097/QAI.0000000000001560] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
98 Takarinda KC, Harries AD, Mutasa-Apollo T, Sandy C, Choto RC, Mabaya S, Mbito C, Timire C. Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018. BMJ Open 2020;10:e034721. [PMID: 32265241 DOI: 10.1136/bmjopen-2019-034721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9:e104557. [PMID: 25105417 DOI: 10.1371/journal.pone.0104557] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
100 Sterling TR, Lin PL. Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis. J Clin Invest 2020;130:5102-4. [PMID: 32831291 DOI: 10.1172/JCI137294] [Reference Citation Analysis]
101 Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr 2015;70:e84-93. [PMID: 26258564 DOI: 10.1097/QAI.0000000000000783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
102 Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA, Denkinger CM, Steingart KR, Shah M. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev 2019;10:CD011420. [PMID: 31633805 DOI: 10.1002/14651858.CD011420.pub3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
103 Rodgers MA, Ameel C, Ellis-Connell AL, Balgeman AJ, Maiello P, Barry GL, Friedrich TC, Klein E, O'Connor SL, Scanga CA. Preexisting Simian Immunodeficiency Virus Infection Increases Susceptibility to Tuberculosis in Mauritian Cynomolgus Macaques. Infect Immun 2018;86:e00565-18. [PMID: 30224552 DOI: 10.1128/IAI.00565-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
104 Peter JG, Theron G, Singh N, Singh A, Dheda K. Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. Eur Respir J 2014;43:185-94. [PMID: 23520317 DOI: 10.1183/09031936.00198012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
105 Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med 2019;40:839-48. [PMID: 31731988 DOI: 10.1016/j.ccm.2019.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
106 Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med 2016;14:50. [PMID: 27004529 DOI: 10.1186/s12916-016-0593-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
107 Mupfumi L, Moyo S, Shin SS, Wang Q, Zetola N, Molebatsi K, Nnawa J, Kgwaadira BT, Bewlay L, Chebani T, Iketleng T, Mogashoa T, Makhema J, Musonda RM, Essex M, Kasvosve I, Gaseitsiwe S. High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National antiretroviral therapy programme between 2011 and 2015. AIDS 2019;33:2415-22. [PMID: 31764106 DOI: 10.1097/QAD.0000000000002363] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 LaCourse SM, Deya RW, Graham SM, Masese LN, Jaoko W, Mandaliya KN, Overbaugh J, McClelland RS. Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 2017;76:74-81. [PMID: 28797022 DOI: 10.1097/QAI.0000000000001461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
109 Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2012;26:2121-33. [PMID: 22695302 DOI: 10.1097/QAD.0b013e3283565dd1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
110 Manavi K, Hodson J. An observational study on the incidence of tuberculosis among a cohort of HIV infected adults in a setting with low prevalence of tuberculosis. HIV Clinical Trials 2016;17:181-8. [DOI: 10.1080/15284336.2016.1201321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Muenchhoff M, Adland E, Roider J, Kløverpris H, Leslie A, Boehm S, Keppler OT, Ndung'u T, Goulder PJR. Differential Pathogen-Specific Immune Reconstitution in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Children. J Infect Dis 2019;219:1407-17. [PMID: 30624717 DOI: 10.1093/infdis/jiy668] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
112 Cohen DB, Meghji J, Squire SB. A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis. Int J Tuberc Lung Dis 2018;22:1127-34. [PMID: 30236179 DOI: 10.5588/ijtld.17.0705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Bachmann MO, Timmerman V, Fairall LR. Effect of antiretroviral treatment on the risk of tuberculosis during South Africa's programme expansion. AIDS 2015;29:2261-8. [PMID: 26544699 DOI: 10.1097/QAD.0000000000000806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
114 Chang CA, Meloni ST, Eisen G, Chaplin B, Akande P, Okonkwo P, Rawizza HE, Tchetgen Tchetgen E, Kanki PJ. Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria. Open Forum Infect Dis 2015;2:ofv154. [PMID: 26613097 DOI: 10.1093/ofid/ofv154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
115 Lawn SD, Wilkinson RJ. ART and prevention of HIV-associated tuberculosis. Lancet HIV 2015;2:e221-2. [PMID: 26423189 DOI: 10.1016/S2352-3018(15)00081-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
116 Githinji LN, Gray DM, Hlengwa S, Machemedze T, Zar HJ. Longitudinal Changes in Spirometry in South African Adolescents Perinatally Infected With Human Immunodeficiency Virus Who Are Receiving Antiretroviral Therapy. Clin Infect Dis 2020;70:483-90. [PMID: 30938406 DOI: 10.1093/cid/ciz255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
117 Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol 2018;16:80-90. [PMID: 29109555 DOI: 10.1038/nrmicro.2017.128] [Cited by in Crossref: 82] [Cited by in F6Publishing: 65] [Article Influence: 20.5] [Reference Citation Analysis]
118 Shapiro AE, van Heerden A, Schaafsma TT, Hughes JP, Baeten JM, van Rooyen H, Tumwesigye E, Celum CL, Barnabas RV. Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in South Africa and Uganda. J Int AIDS Soc 2018;21. [PMID: 29381257 DOI: 10.1002/jia2.25065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
119 Kerkhoff AD, Meintjes G, Opie J, Vogt M, Jhilmeet N, Wood R, Lawn SD. Anaemia in patients with HIV-associated TB: relative contributions of anaemia of chronic disease and iron deficiency. Int J Tuberc Lung Dis 2016;20:193-201. [PMID: 26792471 DOI: 10.5588/ijtld.15.0558] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
120 Musa BM, Musa B, Muhammed H, Ibrahim N, Musa AG. Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria. Ann Thorac Med 2015;10:185-92. [PMID: 26229561 DOI: 10.4103/1817-1737.160838] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
121 Lim JR, Gandhi NR, Mthiyane T, Mlisana K, Moodley J, Jaglal P, Ramdin N, Brust JC, Ismail N, Rustomjee R, Shah NS. Incidence and Geographic Distribution of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. PLoS One 2015;10:e0132076. [PMID: 26147963 DOI: 10.1371/journal.pone.0132076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
122 Wu Y, Yang Y, Wei H, Jia L, Jiang T, Tian Y, Guo C, Zhang Y. Mortality predictors among patients with HIV-associated pulmonary tuberculosis in Northeast China: A retrospective cohort analysis. J Med Virol 2021;93:4901-7. [PMID: 33788289 DOI: 10.1002/jmv.26977] [Reference Citation Analysis]
123 Muyaya LM, Young T, Loveday M. Predictors of mortality in adults on treatment for human immunodeficiency virus-associated tuberculosis in Botswana: A retrospective cohort study. Medicine (Baltimore) 2018;97:e0486. [PMID: 29668628 DOI: 10.1097/MD.0000000000010486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
124 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS 2021;32:780-90. [PMID: 33612015 DOI: 10.1177/0956462421992257] [Reference Citation Analysis]
125 Saharia KK, Koup RA. T cell susceptibility to HIV influences outcome of opportunistic infections. Cell 2013;155:505-14. [PMID: 24243010 DOI: 10.1016/j.cell.2013.09.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]